Razumab both safe and cost-effective for managing retinopathy by prematurity
India: A study published in the Indian Journal of Ophthalmology has concluded that Razumab may be safely used in managing ROP by retina physicians globally. They confirmed it to be safe and cost-effective. They also added that more data will be available to corroborate findings when the use becomes widespread.
In this study entitled, "Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity", researchers have evaluated the efficacy of biosimilar ranibizumab (Razumab) on outcomes of retinopathy of prematurity (ROP) for the first time.
The infants presenting with stage 3+ ROP either in zone 1 or zone 2 posterior or aggressive posterior ROP (APROP) were included in the study and received intravitreal razumab (0.25 mg/0.025 ml) monotherapy.
Follow-up was continued monthly till complete retinal vascularization was achieved, while retreatment with razumab was given when recurrent neovascularization was noted. In case of no recurrence but incomplete vascularization, laser photocoagulation was done to the residual avascular retina.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.